Wendy Rieder

Experience the TriUnity Advantage

Wendy Rieder

Managing Member

Wendy Rieder is a business-oriented attorney with over twenty years of experience in biotechnology, pharmaceutical, dietary supplement, medical device and other life science-related industries. Wendy has been directly responsible for intellectual property, corporate legal, compliance, human resources, quality assurance and business development activities in companies at every stage of development, from virtual start-ups to large commercial entities. 


Most recently, Wendy served as General Counsel and Sr. Vice President, Legal and Intellectual Property for Synta Pharmaceuticals Corp., a NASDAQ-listed pharmaceutical company developing innovative drug candidates for cancer and inflammatory diseases. Prior to Synta, Wendy co-founded Microbiotix, Inc., a privately-held pharmaceutical company focused on developing small molecule anti-infective agents. She has also held positions at Boehringer Ingelheim, Bionutrics, LipoGenics, Ceremedix, Entropin and Fish & Neave (now Ropes & Gray). Wendy is a native New Yorker who holds a bachelor’s degree in chemistry, magna cum laude, from Barnard College, a master’s degree in organic chemistry from Columbia University and a juris doctor degree from Fordham University School of Law. Wendy teaches classes in Compliance in the Life Sciences at Suffolk Law School and FDA Regulatory Law at Northeastern University. She is also a Certified Compliance and Ethics Professional (CCEP), a registered US patent attorney and is licensed to practice law in New York, Connecticut, Massachusetts, and Washington, DC.

Career highlights

  • Started and built the Legal/IP/Compliance function in three different life sciences companies, from start-up phase through mid-size public company. Created contract management system, established SOX-compliant processes and procedures, and advised Board of Directors and management on governance issues.
  • Core member of IPO team at Synta. Managed due diligence process across all functions. Drafted S-1 registration statement and addressed SEC comments.
  • Lead attorney for $1+ billion strategic alliance between Synta and GSK for development and commercialization of  melanoma therapeutic agent.
  • Lead attorney for $1+ billion strategic alliance between Synta and Roche for research and development of CRACM inhibitors.
  • Responsible for entering into more than 30 in- and out-licensing transactions covering biologics, medical devices, platform technology, nutraceutical and pharmaceutical products.
  • Served as Synta’s Chief Compliance Officer, responsible for instituting and overseeing pharma compliance policies and procedures.
  • Acted as interim head of Human Resources, QA and Regulatory Affairs functions at Synta
  • Co-founded biotech company to develop novel anti-infective agents in-licensed from University of Massachusetts Medical School